Difference between revisions of "Vismodegib (Erivedge)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Basal cell | + | *[[Basal cell carcinoma (BCC)]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *1/30/2012: Initial FDA approval "for the treatment of adults with metastatic [[Basal cell | + | *1/30/2012: Initial FDA approval "for the treatment of adults with metastatic [[Basal cell carcinoma (BCC)|basal cell carcinoma]], or with locally advanced [[Basal cell carcinoma (BCC)|basal cell carcinoma]] that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation." |
==Also known as== | ==Also known as== | ||
| − | + | *'''Code name:''' GDC-0449 | |
| + | *'''Brand name:''' Erivedge | ||
==References== | ==References== | ||
| Line 23: | Line 24: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| Line 29: | Line 29: | ||
[[Category:SMO inhibitors]] | [[Category:SMO inhibitors]] | ||
| − | [[Category:Basal cell | + | [[Category:Basal cell carcinoma (BCC) medications]] |
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 15:37, 3 December 2017
General information
Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Erivedge manufacturer side effect tips[4]
- Vismodegib (Erivedge) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/30/2012: Initial FDA approval "for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation."
Also known as
- Code name: GDC-0449
- Brand name: Erivedge